Details of the Drug Combination

General Information of Drug Combination (ID: DCI74MA)

Drug Combination Name
LY3039478 LY2940680
Indication
Disease Entry Status REF
Solid Tumor Phase 1 [1]
Component Drugs LY3039478   DMC5SAW LY2940680   DMTJWIQ
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of LY3039478
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1/2 [1]
T-cell acute lymphoblastic leukaemia 2A90.5 Phase 1/2 [2]
Lymphoma 2A80-2A86 Phase 1 [3]
LY3039478 Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Notch-1 receptor (NOTCH1) TTB1STW NOTC1_HUMAN Inhibitor [2]
Notch-4 receptor (NOTCH4) TTXDIK2 NOTC4_HUMAN Inhibitor [5]
------------------------------------------------------------------------------------
Indication(s) of LY2940680
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1/2 [4]
Ovarian cancer 2C73 Phase 1 [2]
LY2940680 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Smoothened homolog (SMO) TT8J1S3 SMO_HUMAN Modulator [6]
------------------------------------------------------------------------------------
LY2940680 Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [7]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT02784795) A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 ClinicalTrials.gov (NCT01695005) A Study of LY3039478 in Participants With Advanced Cancer. U.S. National Institutes of Health.
4 ClinicalTrials.gov (NCT01722292) A Study of LY2940680 in Small Cell Lung Cancer. U.S. National Institutes of Health.
5 J Clin Oncol 33, 2015 (suppl; abstr 2533).
6 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
7 Phase I study of LY2940680, a Smo antagonist, in patients with advanced cancer including treatment-naive and previously treated basal cell carcinoma. Clin Cancer Res. 2018 May 1;24(9):2082-2091.